

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name ☒ Organization/Lobbying Firm ☐ Self Employed Individual

MEDCO HEALTH SOLUTIONS, INC

2. Address ☐ Check if different than previously reported

Address1 **601 PENNSYLVANIA AVENUE, NW** Address2 **SUITE 700**
City **WASHINGTON, DC** State **DC** Zip Code **20004** - Country **USA**

3. Principal place of business (if different than line 2)

City **Franklin Lakes** State **NJ** Zip Code **07417** - Country **USA**

4a. Contact Name

b. Telephone Number

c. E-mail

5. Senate ID#

PETER BEGANS

☐ International Number

(202) 639-1885

peter_begans@medco.com

89177-12

7. Client Name ☒ Self ☐ Check if client is a state or local government or instrumentality

6. House ID#

MEDCO HEALTH SOLUTIONS, INC

366750000

TYPE OF REPORT

8. Year **2009** Q1 (1/1 - 3/31) ☒ Q2 (4/1 - 6/30) ☐ Q3 (7/1-9/30) ☐ Q4 (10/1 - 12/31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date _____ 11. No Lobbying Issue Activity ☐

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$5,000 ☐

\$5,000 or more ☐ \$ _____

Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$5,000 ☐

\$5,000 or more ☒ \$ **\$ 990,000,000.00**

14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.

- ☒ **Method A.** Reporting amounts using LDA definitions only
- ☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
- ☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Filed Electronically

Date

04/17/2009

Printed Name and Title **Peter Begans, Vice President, Federal Government Affairs**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

HCR

HEALTH ISSUES

(one per page)

16. Specific lobbying issues

Health Information Technology, HIPAA Privacy and Security Rules, Biogenerics, Comparative Effectiveness, Chronic Care Management

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Peter	Begans			<input type="checkbox"/>
Bill	Head			<input checked="" type="checkbox"/>
Kimberly	Linthicum			<input checked="" type="checkbox"/>
Allyson	Blandford			<input checked="" type="checkbox"/>
Heather	Stewart			<input checked="" type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title

Peter Begans, Vice President, Federal Government Affairs

HR 1 - American Recovery and Reinvestment Act of 2009; Title VIII Departments of Labor, Health and Human Services, and Education, and Related Agencies, Healthcare Research and Quality and Title XIII - Health Information Technology for Economic and Clinical Health Act or the HITECH Act

HR 1427 and S. 726 - Promoting Innovation and Access to Life-Saving Medicine Act; all sections.

HR 1548 - Pathway for Biosimilars Act; all aspects

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

MMM

MEDICARE/MEDICAID

(one per page)

16. Specific lobbying issues

Medicare Part D, Antitrust Exemption for Independent Pharmacists, IVIG Payments, Medicare Demonstration Project for Durable Medical Equipment, Importation of Prescription Drugs

17. House(s) of Congress and Federal agencies☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Peter	Begans			<input type="checkbox"/>
Bill	Head			<input checked="" type="checkbox"/>
Kimberly	Linthicum			<input checked="" type="checkbox"/>
Allyson	Blandford			<input checked="" type="checkbox"/>
Heathter	Stewart			<input checked="" type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above☒ Check if None

Printed Name and TitlePeter Begans, Vice President, Federal Government Affairs

HR 574 and S. 254 - Medicare Home Infusion Therapy Coverage Act of 2009; all aspects

HR 1204 - Community Pharmacy Fairness Act of 2009; all sections

HR 1765 - To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program

S. 525 - Pharmaceutical Market Access and Drug Safety Act of 2009; all aspects

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

PHA

PHARMACY

(one per page)

16. Specific lobbying issues

Electronic Prescribing, Mail Order Pharmacy

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Peter	Begans			<input type="checkbox"/>
Bill	Head			<input checked="" type="checkbox"/>
Kimberly	Linthicum			<input checked="" type="checkbox"/>
Allyson	Blandford			<input checked="" type="checkbox"/>
Heather	Stewart			<input checked="" type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title

Peter Begans, Vice President, Federal Government Affairs

HR 1 - American Recovery and Reinvestment Act of 2009; Title XIII - Health Information Technology for Economic and Clinical Health Act or the HITECH Act